448 related articles for article (PubMed ID: 30681239)
1. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
2. Interventions for American cutaneous and mucocutaneous leishmaniasis.
Pinart M; Rueda JR; Romero GA; Pinzón-Flórez CE; Osorio-Arango K; Silveira Maia-Elkhoury AN; Reveiz L; Elias VM; Tweed JA
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004834. PubMed ID: 32853410
[TBL] [Abstract][Full Text] [Related]
3. Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Mendes L; Guerra JO; Costa B; Silva ASD; Guerra MDGB; Ortiz J; Doria SS; Silva GVD; de Jesus DV; Barral-Netto M; Penna G; Carvalho EM; Machado PRL
Int J Infect Dis; 2021 Feb; 103():358-363. PubMed ID: 33253864
[TBL] [Abstract][Full Text] [Related]
4. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
5. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Romero GA; Guerra MV; Paes MG; Macêdo VO
Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
10. Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a
Barroso DH; Gonçalves RT; Barbosa JS; da Motta JOC; Freire GSM; Gomes CM; Sampaio RNR
Front Cell Infect Microbiol; 2022; 12():993338. PubMed ID: 36211958
[TBL] [Abstract][Full Text] [Related]
11. Resistance of
Regli IB; Fernández OL; Martínez-Salazar B; Gómez MA; Saravia NG; Tacchini-Cottier F
Front Immunol; 2018; 9():3040. PubMed ID: 30622537
[No Abstract] [Full Text] [Related]
12. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.
Neves LO; Talhari AC; Gadelha EP; Silva Júnior RM; Guerra JA; Ferreira LC; Talhari S
An Bras Dermatol; 2011; 86(6):1092-101. PubMed ID: 22281895
[TBL] [Abstract][Full Text] [Related]
14. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
15. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
17. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
Machado PRL; Lago A; Cardoso TM; Magalhaes A; Carvalho LP; Lago T; Carvalho AM; Costa R; Carvalho EM
Emerg Infect Dis; 2024 Mar; 30(3):510-518. PubMed ID: 38407142
[TBL] [Abstract][Full Text] [Related]
18. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
[TBL] [Abstract][Full Text] [Related]
19. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
Cataldo JI; Conceição-Silva F; Antônio LF; Schubach AO; Marzochi MCA; Valete-Rosalino CM; Pimentel MIF; Lyra MR; Oliveira RVC; Barros JHDS; Pacheco RDS; Madeira MF
Rev Soc Bras Med Trop; 2018; 51(6):769-780. PubMed ID: 30517530
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
